Sana Ahuja

Sana Ahuja

Auto-generated profile, based on publicly available information

Sana Ahuja

Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 December 2024 in Korean Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SASana Ahuja
Sana Ahuja
SZSufian Zaheer
Sufian Zaheer
Cancer immunotherapy uses the body’s immune system to combat cancer, marking a significant advancement in treatment. This review traces its evolution from the late 19th century to its current status. It began with William Coley’s pioneering work using bacterial toxins to stimulate the immune system against cancer cells, establishing the foundational concept of immunotherapy. In the mid-20th century, cytokine therapies like interferons and interleukins emerged, demonstrating that altering the immune response could reduce tumors and highlighting the complex interplay between cancer and the immune system. The discovery of immune checkpoints, regulatory pathways that prevent autoimmunity but are exploited by cancer cells to evade detection, was a pivotal development. Another major breakthrough is CAR-T cell therapy, which involves modifying a patient’s T cells to target cancer-specific antigens. This personalized treatment has shown remarkable success in certain blood cancers. Additionally, cancer vaccines aim to trigger immune responses against tumor-specific or associated antigens, and while challenging, ongoing research is improving their efficacy. The historical progression of cancer immunotherapy, from Coley’s toxins to modern innovations like checkpoint inhibitors and CAR-T cell therapy, underscores its transformative impact on cancer treatment. As research delves deeper into the immune system’s complexities, immunotherapy is poised to become even more crucial in oncology, offering renewed hope to patients globally.

1 July 2021 in Journal of Cytology
Verified
Journal Article
Open access
PDF file
SASana Ahuja
Sana Ahuja
AMAvneesh Malviya
Avneesh Malviya
Context: The International Academy of Cytology Yokohama System has developed a standardized system of reporting breast cytology by classifying them into five categories – insufficient, benign, atypical, suspicious, and malignant. Numerous studies conducted at different centers are required to confirm the risk of malignancy of the different categories. Aims: The main objectives of our study were to classify breast fine needle aspirates according to the IAC Yokohama system and assess the risk of malignancy, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Settings and Design: It was a retrospective study done over a period of 2 years from January 2018 to December 2020. Materials and Methods: All breast FNAs done in the above period were retrieved and classified into five categories according to the Yokohama system. Histopathological diagnosis was also retrieved wherever available. Statistical Analysis Used: Using a histopathological diagnosis as the gold standard, sensitivity, specificity, PPV, NPV, and diagnostic accuracy were calculated. For each of the five categories, the risk of malignancy was also assessed. Results: Out of the 554 breast fine needle aspirates, 242 had histopathological correlation. The risk of malignancy for insufficient, benign, atypical, suspicious, and malignant categories were 5%, 1.5%, 17.4%, 81.8%, and 100%, respectively. Maximum sensitivity (97.2%) was achieved when atypical, suspicious, and malignant cases were considered as positive test results. The highest specificity (100%) was observed when only malignant cases were considered as positive test results, whereas maximum diagnostic accuracy (96.4%) was noted when the malignant and suspicious category was included in positive test results. Conclusion: The IAC Yokohama system is an excellent system for accurately diagnosing breast fine needle aspirates with greater reproducibility of reports and better communication between the pathologist and clinician.

14 August 2024 in Pathology - Research and Practice
Verified
Journal Article
Closed access
SASana Ahuja
Sana Ahuja
AKAdil Aziz Khan
Adil Aziz Khan
SZSufian Zaheer
Sufian Zaheer


11 October 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
SASana Ahuja
Sana Ahuja
AKAdil Aziz Khan
Adil Aziz Khan
SZSufian Zaheer
Sufian Zaheer
SRSunil Ranga
Sunil Ranga